8-K current report · filed Nov 4, 2026

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) 8-K Current Report: November 4, 2026

Item 1.01Item 2.03Item EX-99.1ARWR overview

Short answer

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item EX-99.1 (Exhibit EX-99.1). $400.0M senior secured facility fully funded November 2, 2026, maturing November 2, 2031.

ARROWHEAD PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $400.0M senior secured facility fully funded November 2, 2026, maturing November 2, 2031
  • Interest reduced from 15.0% paid-in-kind to Term SOFR plus 5.50% or base rate plus 4.50%, payable quarterly in cash
  • $404.4M payoff extinguished approximately $363.8M legacy principal and avoided approximately $68M versus the former 2.0x MOIC obligation
  • Minimum secured unrestricted cash covenant reduced to $125.0M from $150.0M, easing liquidity constraints
  • Greater financing flexibility: no mandatory product-proceeds sweeps and permitted convertible debt capacity up to the greater of $1.1B or 10.0% of market capitalization, capped at $2.5B

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 links financial obligations to Item 1.01, indicating a material agreement created direct debt or payment obligations
  • Investors must review the incorporated Item 1.01 terms to assess amount, interest, maturity and use of proceeds
  • November 4, 2026 press release may contain the obligation’s substantive terms and strategic rationale

Item EX-99.1 · Exhibit EX-99.1

  • $400 million refinancing replaces 15% debt with SOFR plus 5.50%, materially reducing borrowing costs
  • Existing facility retired at a $68 million discount to its contractual minimum repayment amount
  • New loan matures November 2, 2031, extending runway and improving near-term liquidity
  • No scheduled amortization or mandatory revenue, milestone, royalty, or partnership-proceeds sweeps
  • Debt remains senior secured, with principal due at maturity and prepayment premiums including a make-whole through May 2, 2028

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ARROWHEAD PHARMACEUTICALS, INC. 8-K filings

Get the next ARWR 8-K as it lands

Follow ARWR for push alerts, or ask the research agent what this filing means.